JPH08501079A - テロメア長および／またはテロメラーゼ活性に関連した症状の治療および診断 - Google Patents

テロメア長および／またはテロメラーゼ活性に関連した症状の治療および診断

Info

Publication number
JPH08501079A
JPH08501079A JP6503742A JP50374293A JPH08501079A JP H08501079 A JPH08501079 A JP H08501079A JP 6503742 A JP6503742 A JP 6503742A JP 50374293 A JP50374293 A JP 50374293A JP H08501079 A JPH08501079 A JP H08501079A
Authority
JP
Japan
Prior art keywords
cells
cell
telomere
telomerase
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6503742A
Other languages
English (en)
Japanese (ja)
Inventor
ウエスト，マイケル・ディ
シェイ，ジェリー
ライト，ウッドリング
ブラックバーン，エリザベス・エイチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JPH08501079A publication Critical patent/JPH08501079A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/11—Automated chemical analysis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/11—Automated chemical analysis
    • Y10T436/115831—Condition or time responsive

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP6503742A 1992-05-13 1993-05-13 テロメア長および／またはテロメラーゼ活性に関連した症状の治療および診断 Pending JPH08501079A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88243892A 1992-05-13 1992-05-13
US07/882,438 1992-05-13
US08/038,766 1993-03-24
US08/038,766 US5489508A (en) 1992-05-13 1993-03-24 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
PCT/US1993/004546 WO1993023572A1 (fr) 1992-05-13 1993-05-13 Therapie et diagnostic des etats pathologiques lies a la longueur du telomere et/ou a l'activite de la telomerase

Publications (1)

Publication Number Publication Date
JPH08501079A true JPH08501079A (ja) 1996-02-06

Family

ID=26715521

Family Applications (6)

Application Number Title Priority Date Filing Date
JP6503742A Pending JPH08501079A (ja) 1992-05-13 1993-05-13 テロメア長および／またはテロメラーゼ活性に関連した症状の治療および診断
JP10226268A Pending JPH11123100A (ja) 1992-05-13 1998-08-10 テロメラーゼ活性調節剤のスクリーニング方法
JP10226303A Pending JPH11127874A (ja) 1992-05-13 1998-08-10 検出方法
JP11286016A Pending JP2000116388A (ja) 1992-05-13 1999-10-06 検出方法およびテロメラ―ゼ活性調節剤のスクリ―ニング方法
JP2001222342A Withdrawn JP2002101898A (ja) 1992-05-13 2001-07-23 検出方法
JP2005039890A Pending JP2005198659A (ja) 1992-05-13 2005-02-16 検出方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP10226268A Pending JPH11123100A (ja) 1992-05-13 1998-08-10 テロメラーゼ活性調節剤のスクリーニング方法
JP10226303A Pending JPH11127874A (ja) 1992-05-13 1998-08-10 検出方法
JP11286016A Pending JP2000116388A (ja) 1992-05-13 1999-10-06 検出方法およびテロメラ―ゼ活性調節剤のスクリ―ニング方法
JP2001222342A Withdrawn JP2002101898A (ja) 1992-05-13 2001-07-23 検出方法
JP2005039890A Pending JP2005198659A (ja) 1992-05-13 2005-02-16 検出方法

Country Status (6)

Country Link
US (12) US5489508A (fr)
EP (1) EP0642591A4 (fr)
JP (6) JPH08501079A (fr)
AU (2) AU688262B2 (fr)
CA (3) CA2245462C (fr)
WO (1) WO1993023572A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530892A (ja) * 2000-04-20 2003-10-21 シーメグ リミティド 臨床診断のための方法
JP2004512042A (ja) * 2000-10-27 2004-04-22 ソシエテ　デ　プロデユイ　ネツスル　ソシエテ　アノニム 不死化された前骨芽細胞およびその作製方法
JP2006238817A (ja) * 2005-03-04 2006-09-14 Hiroshima Univ 遺伝子導入細胞、及びそれを用いたテロメラーゼ誘導物質の検出方法
JP2011206056A (ja) * 1999-01-07 2011-10-20 Medical Research Council 光学的分取方法

Families Citing this family (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007989A (en) 1992-05-13 1999-12-28 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
US5830644A (en) * 1992-05-13 1998-11-03 Geron Corporation Method for screening for agents which increase telomerase activity in a cell
US5639613A (en) * 1992-05-13 1997-06-17 Board Of Regents, University Of Texas System Methods for cancer diagnosis and prognosis
US5693474A (en) * 1992-05-13 1997-12-02 Board Of Regents, University Of Texas System Methods for cancer diagnosis and prognosis
US5837453A (en) * 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US5648215A (en) * 1992-05-13 1997-07-15 Board Of Regents, The University Of Texas System Telomerase diagnostic methods
US5645986A (en) * 1992-05-13 1997-07-08 Board Of Reagents, The University Of Texas System Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5989807A (en) * 1992-05-13 1999-11-23 Geron Corporation & Board Of Regents Detecting cancerous conditions by assaying for telomerase activity
US5489508A (en) * 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5629154A (en) * 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5686306A (en) * 1992-05-13 1997-11-11 Board Of Regents, The University Of Texas System Methods and reagents for lengthening telomeres
US7067497B2 (en) * 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US5744300A (en) * 1993-03-24 1998-04-28 Geron Corporation Methods and reagents for the identification and regulation of senescence-related genes
US5580726A (en) * 1994-04-29 1996-12-03 Geron Corporation Method and Kit for enhanced differential display
US5863726A (en) * 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
WO1995013382A1 (fr) * 1993-11-12 1995-05-18 Geron Corporation Diagnostic et traitement de desordres lies a la longueur de telomeres et/ou l'activite de la telomerase
WO1995013383A1 (fr) * 1993-11-12 1995-05-18 Geron Corporation Procedes et reactifs pour l'allongement des telomeres
US5804380A (en) * 1993-11-12 1998-09-08 Geron Corporation Telomerase activity assays
EP0666313A3 (fr) * 1994-01-27 1996-03-06 Univ Iowa State Res Found Inc Ciblage de la télomérase dans la thérapie génique du cancer.
EP1293565A3 (fr) * 1994-07-07 2004-05-12 Geron Corporation Composante ARN de la télomérase de mammifères
US5958680A (en) * 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US6013468A (en) * 1994-07-07 2000-01-11 Cold Spring Harbor Laboratory RNA component of telomerase
US5876979A (en) * 1994-07-07 1999-03-02 Cold Spring Harbor Laboratory RNA component of mouse, rat, Chinese hamster and bovine telomerase
DE4428651C1 (de) * 1994-08-12 1996-02-29 Inst Molekulare Biotechnologie Verfahren zur Herstellung und Amplifikation von Nukleinsäuren
US5698686A (en) 1994-10-20 1997-12-16 Arch Development Corporation Yeast telomerase compositions
WO1996019580A2 (fr) * 1994-12-19 1996-06-27 Cold Spring Harbor Laboratory Fraction proteinique de la telomerase
US5643890A (en) * 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
FI100556B (fi) * 1995-03-01 1997-12-31 Biohit Oyj Menetelmä anti-DNA-vasta-aineiden toteamiseksi, diagnostinen menetelmä , reagenssipakkaus ja lääkeaine autoimmuunisairauksia varten
US5700641A (en) * 1995-03-01 1997-12-23 Salonen; Eeva-Marjatta Diagnostic method, test kit, drug and therapeutic treatment for autoimmune diseases
US5703116A (en) * 1995-04-18 1997-12-30 Geron Corporation Telomerase Inhibitors
US5656638A (en) * 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) * 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US7094766B1 (en) * 1995-06-06 2006-08-22 Trustees Of Boston University Use of locally applied DNA fragments
US20030032610A1 (en) * 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
JPH11507839A (ja) * 1995-06-07 1999-07-13 ジェロン コーポレイション テロメラーゼ活性検定
US5840490A (en) * 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5741677A (en) * 1995-06-07 1998-04-21 Geron Corporation Methods for measuring telomere length
AU701903B2 (en) * 1995-06-07 1999-02-11 Cold Spring Harbor Laboratory Essential oligonucleotides of vertebrate telomerase
US6054442A (en) * 1995-07-06 2000-04-25 Board Of Regents, University Of Texas System Methods and compositions for modulation and inhibition of telomerase in vitro
US6004939A (en) 1995-07-06 1999-12-21 Ctrc Research Foundation Board Of Regents Methods for modulation and inhibition of telomerase
US6517834B1 (en) * 1995-08-04 2003-02-11 Geron Corporation Purified telomerase
US5968506A (en) 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
US6545133B1 (en) 1995-08-04 2003-04-08 Geron Corporation Methods for purifying telomerase
US5858777A (en) 1995-09-08 1999-01-12 Geron Corporation Methods and reagents for regulating telomere length and telomerase activity
US5770613A (en) * 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) * 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
ATE362546T1 (de) * 1995-10-12 2007-06-15 Lansdorp Peter M Verfahren zum nachweis von mehrfachkopien einer wiederholungssequenz in einem nukleinsäuremolekül
US6007994A (en) * 1995-12-22 1999-12-28 Yale University Multiparametric fluorescence in situ hybridization
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
JPH09262100A (ja) * 1996-03-27 1997-10-07 Mount Sinai School Medicine City Univ New York テロメラーゼ活性の存在を測定することによる尿試料中のヒト膀胱癌細胞の検出方法
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
AU2445997A (en) * 1996-04-10 1997-10-29 Lynx Therapeutics, Inc. Telomerase inhibitors
WO1997041262A1 (fr) * 1996-05-02 1997-11-06 The Trustees Of Princeton University Determinations de maintenance de telomeres
CA2259389A1 (fr) * 1996-07-01 1998-01-08 Benoit Chabot Composition et procedes permettant de moduler la longueur de telomeres
AU3798997A (en) * 1996-07-17 1998-02-09 David E. Burstein Telomerase assay for precancerous lesions of the uterine cervix
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
KR20000048820A (ko) 1996-10-01 2000-07-25 게론 코포레이션 텔로머라제 역전사 효소
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6808880B2 (en) * 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
WO1998037181A2 (fr) * 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Gene de sous-unite catalytique de telomerase et proteine codee
WO1998037241A1 (fr) * 1997-02-24 1998-08-27 Tm Technologies, Inc. Methode de dosage d'allongement de telomerase
US5919135A (en) * 1997-02-28 1999-07-06 Lemelson; Jerome System and method for treating cellular disorders in a living being
US5830665A (en) * 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6117634A (en) * 1997-03-05 2000-09-12 The Reagents Of The University Of Michigan Nucleic acid sequencing and mapping
US6197557B1 (en) 1997-03-05 2001-03-06 The Regents Of The University Of Michigan Compositions and methods for analysis of nucleic acids
US7413864B2 (en) * 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) * 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US20050013825A1 (en) * 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
US6468983B2 (en) * 1997-04-21 2002-10-22 The Cleveland Clinic Foundation RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
US5871926A (en) * 1997-04-21 1999-02-16 The University Of New Mexico Sensitive method for measurement of telomeric DNA content in human tissues
DE19720151A1 (de) * 1997-05-02 1998-11-05 Max Delbrueck Centrum Chimäre Oligonucleotide und ihre Verwendung
US6268136B1 (en) 1997-06-16 2001-07-31 Exact Science Corporation Methods for stool sample preparation
US6406857B1 (en) 1997-06-16 2002-06-18 Exact Sciences Corporation Methods for stool sample preparation
JP2002514928A (ja) 1997-07-01 2002-05-21 キャンビア バイオシステムス リミティド ライアビリティー カンパニー 脊椎動物テロメラーゼ遺伝子およびタンパク質ならびにその使用
US6054314A (en) * 1997-09-10 2000-04-25 Geron Corporation Method for collecting cells from internal organs
US7378244B2 (en) * 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
US20050084875A1 (en) * 1997-10-24 2005-04-21 University Of Rochester Molecular markers for the diagnosis of Alzheimer's disease
US20020064792A1 (en) * 1997-11-13 2002-05-30 Lincoln Stephen E. Database for storage and analysis of full-length sequences
US6210915B1 (en) 1997-12-31 2001-04-03 University Of Texas Systems Telomerase extraction method
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
US6017709A (en) * 1998-04-29 2000-01-25 University Of Houston DNA replication templates stabilized by guanine quartets
US7270958B2 (en) * 1998-09-10 2007-09-18 The Regents Of The University Of Michigan Compositions and methods for analysis of nucleic acids
ATE319857T1 (de) * 1998-12-14 2006-03-15 Li Cor Inc Kit und methode zur nukleinsäuresequenzierung einzelner moleküle durch polymerase synthese
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension
US6503718B2 (en) 1999-01-10 2003-01-07 Exact Sciences Corporation Methods for detecting mutations using primer extension for detecting disease
ES2269102T3 (es) 1999-02-25 2007-04-01 Exact Sciences Corporation Procedimientos para conservar la integridad del adn.
US20080318889A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
DK1181304T3 (da) * 1999-04-08 2008-02-11 Antisoma Res Ltd Antiproliferativ virkning af G-rige oligonucleotider samt fremgangsmåde til anvendelse af dem til binding af nucleolin
US8114850B2 (en) * 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en) * 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20080318890A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US6964846B1 (en) * 1999-04-09 2005-11-15 Exact Sciences Corporation Methods for detecting nucleic acids indicative of cancer
DE19925839A1 (de) * 1999-06-01 2000-12-07 Universitaetsklinikum Charite Verfahren zur prognostischen Abschätzung des Risikos kognitiver Einschränkungen durch Messung der Telomerenlänge
US6409648B1 (en) 1999-07-01 2002-06-25 The Regents Of The University Of California Polynucleotides encoding TRF1 binding proteins
US20050255596A1 (en) * 1999-09-07 2005-11-17 West Michael D Methods of repairing tandemly repeated DNA sequences and extending cell life-span nuclear transfer
CN1377424A (zh) * 1999-09-07 2002-10-30 先进细胞技术公司 由衰老体细胞克隆的动物中的端粒恢复和细胞寿命延长
US20040180430A1 (en) * 1999-09-07 2004-09-16 West Michael D. Methods of restoring telomere length and extending cell lifespan using nuclear transfer
US6849403B1 (en) 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
US6586177B1 (en) * 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
ATE391134T1 (de) 1999-09-10 2008-04-15 Geron Corp Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung
US6541202B1 (en) 1999-10-13 2003-04-01 Research & Development Institute, Inc. Telomerase reverse transcriptase (TERT) genes from Candida albicans
US6919174B1 (en) * 1999-12-07 2005-07-19 Exact Sciences Corporation Methods for disease detection
AU4714201A (en) * 1999-12-07 2001-06-18 Exact Sciences Corporation Supracolonic aerodigestive neoplasm detection
EP1274410A2 (fr) * 2000-03-31 2003-01-15 Trustees Of Boston University Utilisation de fragments d'adn appliques localement
US7144729B2 (en) 2000-09-01 2006-12-05 Dfb Pharmaceuticals, Inc. Methods and compositions for tissue regeneration
US6428964B1 (en) 2001-03-15 2002-08-06 Exact Sciences Corporation Method for alteration detection
US7563618B2 (en) * 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
US6753411B2 (en) 2001-03-26 2004-06-22 The Regents Of The University Of Colorado Protection-of-telomere-1 (POT-1) proteins
AU2002303277A1 (en) * 2001-04-06 2002-10-21 Vladimir Larionov Artificial chromosomes that can shuttle between bacteria, yeast, and mammalian cells
US7439271B2 (en) * 2001-06-27 2008-10-21 The Gillette Company Reduction of hair growth
US20030082606A1 (en) * 2001-09-04 2003-05-01 Lebo Roger V. Optimizing genome-wide mutation analysis of chromosomes and genes
US7514414B2 (en) 2001-09-24 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Suppressors of CpG oligonucleotides and methods of use
US20040248289A1 (en) * 2001-10-04 2004-12-09 Vladimir Noskov Tandem repeat markers
DE10161829B4 (de) * 2001-12-15 2006-02-16 Peter Lahnert Neue Methode zur Bestimmung der Telomerlänge und ihre Verwendung zur Abschätzung des Lebensalters
JPWO2003054545A1 (ja) * 2001-12-21 2005-04-28 清史 村上 抗テロメラーゼ抗体の検出方法
JP4515767B2 (ja) * 2002-01-31 2010-08-04 ユニバーシティ・オブ・ユタ 非標的核酸依存性増幅の低減：反復核酸配列の増幅
WO2003071252A2 (fr) * 2002-02-15 2003-08-28 Exact Sciences Corporation Procedes d'analyse d'evenements moleculaires
US6916621B2 (en) 2002-03-27 2005-07-12 Spectral Genomics, Inc. Methods for array-based comparitive binding assays
US20040234961A1 (en) * 2002-04-22 2004-11-25 Fordyce Colleen A. Telomere length determination and applications
AU2003263963A1 (en) 2002-08-01 2004-02-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
US20070065830A1 (en) * 2002-09-04 2007-03-22 Children's Hospital Medical Center Of Akron, Inc. Cloning multiple control sequences into chromosomes or into artificial centromeres
US8043622B2 (en) 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
US20060127909A1 (en) * 2002-12-06 2006-06-15 Bernd Schwenzer Polynucleotides targeted against hter and use thereof
WO2004063339A2 (fr) 2003-01-08 2004-07-29 Lesley Davenport Essai de liaison de g-quadruplex et composes utilises a cette fin
US20050113324A1 (en) 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase
CA2513747C (fr) * 2003-01-24 2017-03-07 University Of Utah Procedes permettant de predire le risque de mortalite en mesurant la longueur des telomeres
US20060269924A1 (en) * 2003-04-11 2006-11-30 Trustees Of Boston University Modulation of telomere-initiated cell signaling
US20040259101A1 (en) * 2003-06-20 2004-12-23 Shuber Anthony P. Methods for disease screening
BRPI0414222B8 (pt) 2003-09-09 2021-05-25 Geron Corp compostos oligonucleotídeos modificados para inibição da telomerase, métodos, composição farmacêutica e usos relacionados
US8012693B2 (en) 2003-12-16 2011-09-06 3M Innovative Properties Company Analysis of chemically crosslinked cellular samples
US20080241827A1 (en) * 2004-05-10 2008-10-02 Exact Sciences Corporation Methods For Detecting A Mutant Nucleic Acid
WO2005113769A1 (fr) * 2004-05-14 2005-12-01 Exact Sciences Corporation Procédé servant à stabiliser des échantillons biologiques pour une analyse d'acides nucléiques
US20080108057A1 (en) * 2004-06-22 2008-05-08 Griffith Jeffrey K Allelic imbalance in the diagnosis and prognosis of cancer
WO2006026654A2 (fr) * 2004-08-27 2006-03-09 Exact Sciences Corporation Procede pour detecter une recombinaison
US20090162839A1 (en) * 2004-08-31 2009-06-25 Board Of Regents, The University Of Texas System Diagnosis and prognosis of cancer based on telomere length as measured on cytological specimens
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
CA2598008A1 (fr) * 2005-02-18 2006-08-31 David P. Gilley Methode diagnostique de detection precoce des cancers
CN101193643A (zh) * 2005-03-25 2008-06-04 Alt解决方案公司 端粒酶阳性细胞中端粒长度的调节和癌症治疗
US9777314B2 (en) * 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
EP1891433B1 (fr) * 2005-06-16 2012-03-07 3M Innovative Properties Company Procédé de classification d'échantillons cellulaires chimiquement réticulés par spectre de masse
US20080119492A1 (en) * 2005-07-29 2008-05-22 Jean-Marie Lehn Compositions and methods for treating cancer and other diseases characterized by abnormal cell proliferation
US8153604B2 (en) * 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
ES2696828T3 (es) 2006-10-30 2019-01-18 Geron Corp Inhibidor de telomerasa y gemcitabina combinados para el tratamiento del cáncer
ES2407957T3 (es) * 2007-03-09 2013-06-17 Geron Corporation Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa
CA2703060A1 (fr) * 2007-10-22 2009-04-30 The Wistar Institute Procede d'identification d'un compose modulant l'activite telomerase
US8377992B2 (en) * 2007-10-22 2013-02-19 The Wistar Institute TRBD-binding effectors and methods for using the same to modulate telomerase activity
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
LT3029154T (lt) 2008-10-17 2017-12-27 Geron Corporation Paciento jautrumo telomerazės slopinimo terapijai nustatymo būdas
WO2010075413A1 (fr) 2008-12-22 2010-07-01 University Of Utah Research Foundation Pcr quantitative multiplex monochrome
CN104997774A (zh) 2009-04-10 2015-10-28 齐海燕 新的抗衰老试剂及其鉴别方法
WO2010148212A2 (fr) * 2009-06-17 2010-12-23 Georgetown University Une longueur courte du télomère sur le chromosome 9p est fortement associée à un risque de cancer du sein
WO2011062997A2 (fr) 2009-11-17 2011-05-26 Musc Foundation For Research Development Anticorps monoclonaux humains pour nucléoline humaine
WO2011106671A1 (fr) * 2010-02-26 2011-09-01 Geron Corporation Dosage de l'activité de la télomérase
MY161567A (en) † 2010-04-16 2017-04-28 Zeus Scientific Inc Methods for measuring enzyme activity useful in determining cell viability in non-purified samples
GB201020860D0 (en) * 2010-12-09 2011-01-26 Univ Wolverhampton Disulfiram formulation and uses thereof
SG11201504209YA (en) 2012-11-30 2015-06-29 Geron Corp Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
NZ708920A (en) 2012-12-07 2020-08-28 Geron Corp Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US10316366B2 (en) 2013-05-22 2019-06-11 Telomere Diagnostics, Inc. Measures of short telomere abundance
JP6529486B2 (ja) 2013-06-05 2019-06-12 バイオタイム インク．Ｂｉｏｔｉｍｅ Ｉｎｃ． 哺乳動物種における誘導組織再生のための組成物および方法
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
JP2017205021A (ja) * 2014-09-26 2017-11-24 Jsr株式会社 初代癌細胞のスフェロイド作製方法、スフェロイド、スクリーニング方法、及び、診断方法
CA2971169A1 (fr) 2014-12-30 2016-07-07 Telomere Diagnostics, Inc. Pcr quantitative multiplex
US11156599B2 (en) 2015-03-19 2021-10-26 The Johns Hopkins University Assay for telomere length regulators
JP6202029B2 (ja) * 2015-03-26 2017-09-27 富士ゼロックス株式会社 樹脂組成物及び樹脂成形体
JP7157981B2 (ja) 2016-03-07 2022-10-21 チャールストンファーマ， エルエルシー 抗ヌクレオリン抗体
EP3468605A4 (fr) 2016-06-08 2020-01-08 President and Fellows of Harvard College Vecteur viral modifié réduisant l'induction de réponses inflammatoires et immunitaires
WO2019094548A1 (fr) 2017-11-08 2019-05-16 President And Fellows Of Harvard College Compositions et procédés d'inhibition de réponses inflammatoires induites par un vecteur viral
US10098922B1 (en) 2017-11-30 2018-10-16 Optigenex, Inc. Increasing telomere length in a cell

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737454A (en) * 1983-07-14 1988-04-12 Molecular Diagnostics, Inc. Fast photochemical method of labelling nucleic acids for detection purposes in hybridization assays
US4735778A (en) * 1985-08-28 1988-04-05 Kureha Kagaku Kohyo Kabushiki Kaisha Microtiter plate
US5645986A (en) * 1992-05-13 1997-07-08 Board Of Reagents, The University Of Texas System Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5489508A (en) * 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US5583016A (en) * 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5643890A (en) * 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011206056A (ja) * 1999-01-07 2011-10-20 Medical Research Council 光学的分取方法
JP2003530892A (ja) * 2000-04-20 2003-10-21 シーメグ リミティド 臨床診断のための方法
JP2004512042A (ja) * 2000-10-27 2004-04-22 ソシエテ　デ　プロデユイ　ネツスル　ソシエテ　アノニム 不死化された前骨芽細胞およびその作製方法
JP4707304B2 (ja) * 2000-10-27 2011-06-22 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 不死化された前骨芽細胞およびその作製方法
JP2006238817A (ja) * 2005-03-04 2006-09-14 Hiroshima Univ 遺伝子導入細胞、及びそれを用いたテロメラーゼ誘導物質の検出方法
JP4635196B2 (ja) * 2005-03-04 2011-02-16 国立大学法人広島大学 遺伝子導入細胞、及びそれを用いたテロメラーゼ誘導物質の検出方法

Also Published As

Publication number Publication date
CA2245461C (fr) 2001-06-26
JP2000116388A (ja) 2000-04-25
CA2135648A1 (fr) 1993-11-25
CA2245461A1 (fr) 1993-11-25
CA2135648C (fr) 2002-06-25
EP0642591A1 (fr) 1995-03-15
US5489508A (en) 1996-02-06
US20060172960A1 (en) 2006-08-03
JP2005198659A (ja) 2005-07-28
US20020127634A1 (en) 2002-09-12
JP2002101898A (ja) 2002-04-09
CA2245462C (fr) 2002-06-25
US20030175766A1 (en) 2003-09-18
AU688262B2 (en) 1998-03-12
JPH11123100A (ja) 1999-05-11
US6194206B1 (en) 2001-02-27
AU8949598A (en) 1999-01-07
US6368789B1 (en) 2002-04-09
CA2245462A1 (fr) 1993-11-25
US5840495A (en) 1998-11-24
AU4374093A (en) 1993-12-13
JPH11127874A (ja) 1999-05-18
US20070010476A1 (en) 2007-01-11
US20040198659A1 (en) 2004-10-07
EP0642591A4 (fr) 1995-05-31
US5707795A (en) 1998-01-13
US5695932A (en) 1997-12-09
US5686245A (en) 1997-11-11
WO1993023572A1 (fr) 1993-11-25

Similar Documents

Publication Publication Date Title
JPH08501079A (ja) テロメア長および／またはテロメラーゼ活性に関連した症状の治療および診断
US5645986A (en) Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US6007989A (en) Methods of screening for compounds that derepress or increase telomerase activity
US5624824A (en) Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US5728521A (en) Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
AU669367B2 (en) Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
WO1995013382A1 (fr) Diagnostic et traitement de desordres lies a la longueur de telomeres et/ou l'activite de la telomerase
Chambon et al. Animal Nuclear DNA-Dejrendent RNA Polymerases
JPH09501562A (ja) ヒト・免疫不全ウイルスに対する活性を有するオリゴヌクレオチド
US5830644A (en) Method for screening for agents which increase telomerase activity in a cell
JPH10501421A (ja) ヒト・免疫不全ウイルスの増殖阻害化合物および方法
Bailey et al. Adenovirus type 12-induced fragility of the human RNU2 locus requires U2 small nuclear RNA transcriptional regulatory elements
US20030190638A1 (en) Methods of screening for compounds that derepress or increase telomerase activity
US6294332B1 (en) Composition and methods for modulating the length of telomeres
AU726528B2 (en) Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
AU735840B2 (en) Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
JP4496362B2 (ja) 抗癌剤の効果を判定するミトコンドリアｄｎａの体細胞変異の検出
Freed et al. Cultured haploid cells resistant to antitubulins
Lindgren Maintenance of genome integrity via activities of the cohesin network
Behie Role of protein kinase CK2a in Leishmania survival and differentiation